Smallpox (vaccinia) vaccine, live - Biologic Drug Details

Summary for smallpox (vaccinia) vaccine, live

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1
Recent Clinical Trials:	See clinical trials for smallpox (vaccinia) vaccine, live

Recent Clinical Trials for smallpox (vaccinia) vaccine, live

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
CJ HealthCare Corporation	Phase 3
Seoul National University Hospital	Phase 3
HK inno.N Corporation	Phase 3

See all smallpox (vaccinia) vaccine, live clinical trials

Pharmacology for smallpox (vaccinia) vaccine, live

Physiological Effect	Actively Acquired Immunity
Established Pharmacologic Class	Live Vaccinia Virus Vaccine
Chemical Structure	Smallpox Vaccine Vaccines, Live, Unattenuated

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for smallpox (vaccinia) vaccine, live Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for smallpox (vaccinia) vaccine, live Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Emergent Product Development Gaithersburg, Inc.	ACAM2000	smallpox (vaccinia) vaccine, live	For Injection	125158	10,034,954	2034-03-11	DrugPatentWatch analysis and company disclosures
Emergent Product Development Gaithersburg, Inc.	ACAM2000	smallpox (vaccinia) vaccine, live	For Injection	125158	10,064,923	2033-12-10	DrugPatentWatch analysis and company disclosures
Emergent Product Development Gaithersburg, Inc.	ACAM2000	smallpox (vaccinia) vaccine, live	For Injection	125158	10,245,341	2038-05-25	DrugPatentWatch analysis and company disclosures
Emergent Product Development Gaithersburg, Inc.	ACAM2000	smallpox (vaccinia) vaccine, live	For Injection	125158	10,314,878	2035-07-17	DrugPatentWatch analysis and company disclosures
Emergent Product Development Gaithersburg, Inc.	ACAM2000	smallpox (vaccinia) vaccine, live	For Injection	125158	10,342,883	2035-03-23	DrugPatentWatch analysis and company disclosures
Emergent Product Development Gaithersburg, Inc.	ACAM2000	smallpox (vaccinia) vaccine, live	For Injection	125158	10,653,745	2037-08-25	DrugPatentWatch analysis and company disclosures
Emergent Product Development Gaithersburg, Inc.	ACAM2000	smallpox (vaccinia) vaccine, live	For Injection	125158	10,688,172	2038-11-29	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for smallpox (vaccinia) vaccine, live Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Emergent Product Development Gaithersburg, Inc.	ACAM2000	smallpox (vaccinia) vaccine, live	For Injection	125158	10,076,569	2036-08-11	Patent claims search
Emergent Product Development Gaithersburg, Inc.	ACAM2000	smallpox (vaccinia) vaccine, live	For Injection	125158	10,105,436	2036-08-11	Patent claims search
Emergent Product Development Gaithersburg, Inc.	ACAM2000	smallpox (vaccinia) vaccine, live	For Injection	125158	10,238,700	2034-12-31	Patent claims search
Emergent Product Development Gaithersburg, Inc.	ACAM2000	smallpox (vaccinia) vaccine, live	For Injection	125158	10,851,350	2038-06-27	Patent claims search
Emergent Product Development Gaithersburg, Inc.	ACAM2000	smallpox (vaccinia) vaccine, live	For Injection	125158	10,857,225	2038-07-24	Patent claims search
Emergent Product Development Gaithersburg, Inc.	ACAM2000	smallpox (vaccinia) vaccine, live	For Injection	125158	8,691,502	2031-05-02	Patent claims search
Emergent Product Development Gaithersburg, Inc.	ACAM2000	smallpox (vaccinia) vaccine, live	For Injection	125158	9,416,371	2034-01-27	Patent claims search

International Patents for smallpox (vaccinia) vaccine, live

Country	Patent Number	Estimated Expiration
South Korea	20110116018
Israel	275017
Japan	2019171154
Singapore	174108
Japan	WO2013094373
Australia	2008231721
Australia	2012236479

Supplementary Protection Certificates for smallpox (vaccinia) vaccine, live

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2013/053	Ireland		PRODUCT NAME: LIVE MODIFIED VACCINA VIRUS ANKARA; REGISTRATION NO/DATE: EU/1/13/855 20130731
301207	Netherlands		PRODUCT NAME: TEZEPELUMAB; REGISTRATION NO/DATE: EU/1/22/1677 20220920
20C1052	France		PRODUCT NAME: SPECIALITE VACCINALE A BASE DE FHBP DE LA SOUS-FAMILLE A DE NEISSERIA MENINGITIDIS DE SEROGROUPE B ET DE FHBP DE LA SOUS-FAMILLE B DE NEISSERIA MENINGITIDIS DE SEROGROUPE B; REGISTRATION NO/DATE: EU/1/17/1187 20170530
C300610	Netherlands		PRODUCT NAME: GEINACTIVEERD CHIMERISCH FLAVIVIRUS, STAM YF-WN; REGISTRATION NO/DATE: EU/2/13/151 20130606
809	Finland
PA2022016	Lithuania		PRODUCT NAME: TEZEPELUMABAS; REGISTRATION NO/DATE: EU/1/22/1677 20220919
SPC/GB13/067	United Kingdom		PRODUCT NAME: LIVE MODIFIED VACCINIA VIRUS ANKARA; REGISTERED: UK C(2013)5144 20130805; UK EU/1/13/855 20130805

Smallpox (Vaccinia) Vaccine, Live: Market Dynamics and Financial Trajectory

Last updated: February 19, 2026

Market Overview: Demand Drivers and Competitive Landscape

The market for the smallpox (vaccinia) vaccine, live, is primarily driven by national biodefense stockpiles and sporadic outbreaks. Global demand is concentrated among governmental health agencies, specifically those responsible for maintaining the Strategic National Stockpile (SNS) in the United States and similar reserves in other nations. The U.S. government, through the Biomedical Advanced Research and Development Authority (BARDA), has been a consistent purchaser, acquiring vaccine doses to ensure preparedness against potential bioterrorism threats. This demand is largely insulated from typical commercial market forces.

Key factors influencing demand include:

• Geopolitical Tensions: Increased global instability can lead to higher procurement levels for biodefense materials.
• Public Health Preparedness Mandates: Government directives and international health regulations stipulate minimum reserve levels for critical medical countermeasures.
• Epidemiological Surveillance: Any reported re-emergence or heightened risk of orthopoxvirus infections globally can trigger immediate procurement actions.

The competitive landscape for the vaccinia vaccine, live, is highly concentrated. Currently, Bavarian Nordic A/S is the dominant supplier, holding the primary contract with the U.S. government for its JYNNEOS® (Imvanex® in Europe, Imvamune® in Canada) vaccine. This lyophilized, modified vaccinia Ankara-Bavarian Nordic (MVA-BN) strain vaccine is approved for the prevention of smallpox, mpox, and vaccinia disease in adults. Previous generations of vaccinia vaccines, such as DryVax®, were discontinued due to safety concerns and are no longer commercially available or stockpiled.

The market is characterized by:

• High Barriers to Entry: The rigorous regulatory approval process for vaccines, especially for biodefense purposes, requires significant investment and expertise.
• Government Procurement Dominance: The majority of sales are direct contracts with national health authorities, with limited over-the-counter or hospital sales.
• Limited Global Production Capacity: Only a few manufacturers possess the specialized facilities and regulatory compliance to produce these live viral vaccines at scale.

The market's financial trajectory is not driven by typical pharmaceutical sales models. Revenue is primarily derived from large, multi-year government contracts rather than widespread patient use. The valuation of companies in this niche segment is therefore linked to the security and duration of these government agreements and their ability to maintain manufacturing readiness.

Regulatory Landscape and Patent Protection

The regulatory pathway for live vaccinia vaccines is stringent, reflecting their use as critical countermeasures. In the United States, the Food and Drug Administration (FDA) oversees the approval and supply of such vaccines. The primary approval mechanism for products like JYNNEOS® for biodefense applications involves demonstrating efficacy and safety, often supported by data from animal models and, where ethically permissible, human studies.

Key regulatory considerations include:

• FDA Approval: Obtaining and maintaining FDA approval is a prerequisite for inclusion in national stockpiles. JYNNEOS® received FDA approval in 2019 for the prevention of smallpox, mpox, and vaccinia disease.
• Manufacturing Facility Compliance: Production facilities must adhere to strict Current Good Manufacturing Practices (cGMP) standards. Regulatory inspections are routine and critical for maintaining supply agreements.
• Emergency Use Authorization (EUA): In situations of a declared public health emergency, vaccines may be deployed under an EUA, which allows for expanded use based on available evidence, even before full licensure for all intended indications. However, for biodefense, established licensure is preferred for long-term planning.

Patent protection plays a crucial role in securing market exclusivity for vaccine developers. For Bavarian Nordic's JYNNEOS®, patent families cover aspects of the MVA-BN strain, the manufacturing process, and specific formulations. These patents are designed to prevent competitors from producing or selling similar products for a defined period.

Key patent aspects:

• Composition of Matter Patents: Protecting the genetic makeup and characteristics of the MVA-BN strain.
• Process Patents: Covering the specific methods used to cultivate, purify, and formulate the live vaccinia virus.
• Formulation Patents: Protecting the stabilizers and excipients used to ensure vaccine stability and shelf life, particularly important for lyophilized vaccines stored for extended periods.

Patent expiry dates are critical for strategic planning. Companies holding key patents can leverage them to maintain a de facto monopoly until their expiry. Post-patent expiry, the market could theoretically open to generic or biosimilar competition, although the specialized nature of live viral vaccine manufacturing and the high regulatory hurdles make rapid entry challenging.

Financial Performance and Investment Outlook

The financial trajectory of live vaccinia vaccine manufacturers is characterized by a reliance on long-term government contracts rather than high-volume sales typical of commercial pharmaceuticals. Revenue streams are largely predictable, based on agreed-upon delivery schedules and pricing structures within these contracts.

Bavarian Nordic A/S is the primary publicly traded entity in this specific vaccine market. Its financial performance related to the vaccinia vaccine is directly tied to its contracts with the U.S. government.

Key financial metrics and considerations:

• Contract-Based Revenue: The majority of revenue for JYNNEOS® originates from the U.S. government's Strategic National Stockpile (SNS) procurement. This typically involves multi-year orders with fixed delivery quantities and prices.
• Backlog: The company's order backlog from government agencies serves as a key indicator of future revenue. A substantial and stable backlog provides financial visibility.
• Government Funding: BARDA and similar agencies often provide funding for manufacturing scale-up, stockpiling, and research and development, which can influence the financial health and strategic direction of the company.
• Profitability: Profit margins on government contracts can vary but are generally designed to ensure reliable supply and manufacturing capacity. The lack of direct competition allows for a relatively stable pricing environment.

The investment outlook for companies focused on live vaccinia vaccines is primarily dictated by the continued commitment of governments to biodefense preparedness.

Investment factors:

• Contract Renewals and Extensions: The renewal or extension of existing government contracts is crucial for sustained revenue.
• Geopolitical Risk Premium: Periods of heightened geopolitical tension or emerging infectious disease threats can increase government procurement and investor interest.
• Pipeline Diversification: While the vaccinia vaccine is a core asset, the financial stability and growth potential of a company are also influenced by its broader product pipeline and diversification into other therapeutic areas or vaccine types.
• Manufacturing Capacity and Readiness: Investors assess a company's ability to maintain and scale its manufacturing capabilities to meet government demand, which is a significant capital investment.

The market's financial structure is more akin to a defense contractor supplying essential materials than a typical pharmaceutical company selling to healthcare providers and patients. This leads to a valuation model that prioritizes contract security, supply chain reliability, and regulatory compliance over market share expansion in a broad commercial sense.

Manufacturing and Supply Chain Considerations

The production of live vaccinia vaccines involves specialized manufacturing processes and infrastructure, posing significant challenges for supply chain reliability and scalability. The live viral nature of the vaccine necessitates stringent biosafety protocols and specialized containment facilities.

Key manufacturing aspects:

• Cell Culture-Based Production: Vaccinia virus is typically grown in embryonated chicken eggs or various mammalian cell lines. The choice of host system influences scalability, yield, and regulatory considerations.
• Downstream Processing: Harvesting, purification, and concentration of the viral particles require specialized techniques to maintain viral integrity and remove impurities.
• Lyophilization (Freeze-Drying): For long-term storage and stability required by stockpiles, the vaccine is often lyophilized. This process removes water, creating a stable powder that can be reconstituted for administration. Lyophilization requires precise control of temperature and pressure.
• Quality Control: Extensive testing is required at multiple stages of production to ensure viral potency, purity, absence of contaminants, and sterility. This includes batch release testing for every lot produced.

The supply chain for live vaccinia vaccines is characterized by its complexity and the critical role of government oversight.

Supply chain dynamics:

• Single-Source Dominance: The high barriers to entry mean that often only one or a limited number of manufacturers can produce the vaccine at any given time. This creates a significant reliance on that single supplier for national stockpiles.
• Government-Managed Stockpiles: Governments manage the procurement, storage, and distribution of these vaccines. This involves complex logistics, including cold chain maintenance for the finished product, and regular inventory management and rotation.
• Raw Material Sourcing: Securing reliable sources of essential raw materials, such as cell culture media, growth factors, and excipients for lyophilization, is critical. These may also be subject to limited suppliers or specific quality requirements.
• Manufacturing Capacity Fluctuations: While governments may contract for specific quantities, maintaining manufacturing capacity at readiness levels requires ongoing investment and operational expenditure, even between large orders. This can lead to challenges in rapidly scaling up production if demand surges unexpectedly.
• Regulatory Compliance Across Jurisdictions: Manufacturers supplying multiple countries must navigate diverse regulatory requirements for product registration, manufacturing site inspections, and import/export.

The financial health of companies in this sector is directly linked to their ability to consistently meet these demanding manufacturing and supply chain requirements. Investment in advanced manufacturing technologies, robust quality assurance systems, and strategic partnerships for raw material sourcing are essential for ensuring a secure and reliable supply.

Key Takeaways

• The market for smallpox (vaccinia) vaccine, live, is dominated by government biodefense procurement, primarily through long-term contracts.
• Bavarian Nordic A/S is the principal supplier, with its JYNNEOS® vaccine forming the cornerstone of national stockpiles, particularly in the U.S.
• High regulatory barriers, specialized manufacturing, and limited competition create significant entry hurdles.
• Financial performance is contract-driven, with revenue predictability tied to government agreements rather than commercial sales volume.
• Patent protection for vaccine composition and manufacturing processes is crucial for maintaining market exclusivity.
• Supply chain reliability hinges on specialized manufacturing capabilities, strict quality control, and government inventory management.

Frequently Asked Questions

1. What is the primary driver for the current demand for live vaccinia vaccines? The primary driver is government procurement for national biodefense stockpiles, aimed at preparedness against potential bioterrorism or accidental release of orthopoxviruses.

2. Who are the main competitors in the live vaccinia vaccine market? Currently, Bavarian Nordic A/S is the dominant player. The market is characterized by high barriers to entry, limiting the number of active competitors.

3. How is the financial trajectory of live vaccinia vaccine manufacturers different from typical pharmaceutical companies? Revenue is derived from multi-year government contracts rather than broad patient prescriptions or commercial sales, leading to a more predictable but less volatile financial model.

4. What are the main challenges in manufacturing live vaccinia vaccines? Challenges include specialized live viral production, stringent biosafety requirements, complex downstream processing, lyophilization for stability, and rigorous quality control protocols.

5. What is the role of patent protection in this market? Patents on the vaccine strain, manufacturing processes, and formulations are essential for securing market exclusivity and ensuring a return on investment for developers in this niche, high-cost sector.

Citations

[1] U.S. Food and Drug Administration. (2019, September 24). FDA approves JYNNEOS® to prevent smallpox and mpox. U.S. Food & Drug Administration. Retrieved from https://www.fda.gov/news-events/press-announcements/fda-approves-jynneos-prevent-smallpox-and-mpox